An investigation on behalf of investors of Kezar Life Sciences, Inc. (NASDAQ: KZR) shares over potential securities laws violations by Kezar Life Sciences, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Kezar Life Sciences, Inc. (NASDAQ: KZR) concerning whether a series of statements by Kezar Life Sciences, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Francisco, CA based Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Kezar Life Sciences, Inc. went public in June 2018 and sold 5 million shares at $15 per share.

Since then, shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) declined to as low as $5.65 per share on July 18, 2019.

On July 23, 2019, NASDAQ: KZR shares closed at $6.00 per share.